Currently, the correction of SMN2 gene splicing is one of the most effective approaches to SMA therapy, along with the delivery of a functional copy of the SMN1 gene into the cells of SMA patients [5]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.